Ideaya Biosciences Inc (IDYA) Stock Price, Quote & News

Company Profile

IDEAYA Biosciences, Inc., a precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 2 clinical trials for patients with solid tumor...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 443 6209

Website: www.ideayabio.com

Address:

5000 Shoreline Court, Suite 300, South San Francisco, United States

LiquidThetaLEAPS Oct. 25 at 12:57 PM

LiquidTheta® LEAPS LIVE Actionable Alert Asset: $IDYA Current Share Price: $29.18 Contracts: $IDYA April 17, 2026 $30 Calls Scale in: $5.51- $6.74 Scale out: $8.57-$11.03 Can Easily Capture: 60% ROI Blended DTE: 174 Days | Join Elites here: https://liquidtheta.com

0 · Reply

JackDarwin Oct. 25 at 9:15 AM

$IDYA Above the Stomach Candlestick Pattern

0 · Reply

HolEKa1010 Oct. 24 at 3:22 PM

$IDYA okay I see the movement

0 · Reply

LiquidThetaLEAPS Oct. 23 at 10:38 PM

LiquidTheta® LEAPS LIVE Actionable Alert Asset: $IDYA Current Share Price: $28.50 Contracts: $IDYA April 17, 2026 $30 Calls Scale in: $5.49- $6.71 Scale out: $8.54-$10.98 Can Easily Capture: 60% ROI Blended DTE: 176 Days | Join Elites here: https://liquidtheta.com/options

0 · Reply

JarvisFlow Oct. 23 at 3:53 PM

JP Morgan has updated their rating for IDEAYA Biosciences ( $IDYA ) to Overweight with a price target of 79.

0 · Reply

Quantumup Oct. 23 at 11:30 AM

JPMorgan⬆️the PT on $IDYA to $79 from $74, reiterated at an Overweight, and⬆️ darovasertib's probability of success (PoS) in the neoadjuvant setting to 70% from 60%—estimates peak sales of $500M in the U.S. alone—sees share upside into the mUM update. $IMCR $PFE $MRK $BMY

0 · Reply

AVXLIMMINENTZERO Oct. 23 at 7:50 AM

0 · Reply

LiquidThetaLEAPS Oct. 23 at 1:12 AM

LiquidTheta® LEAPS LIVE Actionable Alert Asset: $IDYA Current Share Price: $28.64 Contracts: $IDYA April 17, 2026 $30 Calls Scale in: $5.54- $6.77 Scale out: $8.61-$11.07 Can Easily Capture: 60% ROI Blended DTE: 177 Days | Join Elites here: https://liquidtheta.com/options

0 · Reply

CH_Expat Oct. 22 at 6:56 PM

$IDYA Make of it what you want, but still the one bio I would still open a NEW position with most confidence.

0 · Reply

US_Bull Oct. 22 at 3:55 PM

$IDYA Started a position at 27,5$, 1,300 shares.

0 · Reply

IDEAYA Biosciences Announces Positive Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma in a Proffered Paper Oral Presentation at ESMO 2025

Oct 20, 2025, 6:00 AM EDT - 5 days ago

IDEAYA Biosciences Reports Positive Median Overall Survival Data from Phase 2 Trial of the Darovasertib and Crizotinib Combination in First-line Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress

Sep 26, 2025, 6:00 AM EDT - 4 weeks ago

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Sep 8, 2025, 6:41 PM EDT - 6 weeks ago

IDEAYA Biosciences, Inc. (IDYA) 10-Year Anniversary R&D Day (Transcript)

Sep 8, 2025, 4:30 PM EDT - 6 weeks ago

IDEAYA Biosciences: Positive Darovasertib Data In Neo-Adjuvant Melanoma Sets Next Catalyst

Sep 8, 2025, 8:00 AM EDT - 6 weeks ago

IDEAYA Biosciences Announces Positive Data From Phase 1/2 Combination Trial of IDE397, a potential first-in-class MAT2A inhibitor, and Trodelvy® in MTAP-Deletion Urothelial Cancer

Sep 8, 2025, 6:00 AM EDT - 6 weeks ago

IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma

Sep 7, 2025, 12:00 PM EDT - 6 weeks ago

IDEAYA Biosciences and Hengrui Pharma Present Positive Phase 1 Data for IDE849 (SHR-4849), a Potential First-in-Class DLL3 TOP1 ADC, in Small Cell Lung Cancer at the IASLC 2025 World Conference on Lung Cancer

Sep 4, 2025, 6:00 AM EDT - 7 weeks ago

IDEAYA Biosciences Announces First-Patient-In for Phase 1/2 Combination Trial of IDE397, A Potential First-in-Class MAT2A Inhibitor, and Trodelvy® in MTAP-Deletion Non-Small Cell Lung Cancer

Sep 3, 2025, 10:15 PM EDT - 7 weeks ago

IDEAYA Biosciences, Inc. (IDYA) Presents At Cantor Global Healthcare Conference 2025 Transcript

Sep 3, 2025, 6:00 AM EDT - 7 weeks ago

IDEAYA Biosciences Announces IND Submission for IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deletion Solid Tumors

Sep 2, 2025, 6:00 AM EDT - 7 weeks ago

Servier and IDEAYA Biosciences Partner to Bring Darovasertib, a Promising Uveal Melanoma Treatment, to Patients Worldwide

Aug 29, 2025, 2:00 PM EDT - 2 months ago

IDEAYA Biosciences to Present First Median Overall Survival Data from Phase 2 Trial of the Darovasertib / Crizotinib Combination in Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress

Aug 25, 2025, 6:00 AM EDT - 2 months ago

IDEAYA Biosciences to Participate in Upcoming September 2025 Investor Relations Events

Aug 18, 2025, 6:00 AM EDT - 2 months ago

IDEAYA Biosciences Announces Agenda for 10-Year Anniversary R&D Day on September 8, 2025

Aug 5, 2025, 8:43 AM EDT - 2 months ago

Ideaya Biosciences: Moving Into ADCs For Solid Tumors

Aug 5, 2025, 6:00 AM EDT - 2 months ago

IDEAYA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 24, 2025, 9:25 AM EDT - 3 months ago

IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2025 for Phase 2 Clinical Trial of Neoadjuvant Darovasertib in Primary Uveal Melanoma

Jul 23, 2025, 6:00 AM EDT - 3 months ago

IDEAYA Biosciences Announces 10-Year Anniversary R&D Day on September 8, 2025 to Present Multiple Clinical Data Updates and Outline Future Growth Strategy

Jul 22, 2025, 1:01 PM EDT - 3 months ago

IDEAYA Biosciences and Hengrui Pharmaceuticals Announce Oral Presentation at IASLC 2025 World Conference on Lung Cancer for IDE849 (SHR-4849), a Potential First-in-Class DLL3-TOP1 ADC

Jul 21, 2025, 6:00 AM EDT - 3 months ago

IDEAYA Biosciences to Participate in Upcoming July 2025 Investor Relations Event

Jun 2, 2025, 6:00 AM EDT - 5 months ago

IDEAYA Biosciences to Participate in Upcoming June 2025 Investor Relations Events

May 14, 2025, 5:30 PM EDT - 5 months ago

Ideaya Biosciences: Value Beyond Darovasertib With ADC Program IDE849

May 6, 2025, 6:05 AM EDT - 6 months ago

IDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update

May 6, 2025, 6:00 AM EDT - 6 months ago

IDEAYA Biosciences Announces US FDA IND-Clearance for IDE849, a Potential First-in-Class DLL3 TOP1 ADC, for a Phase 1 Study in Solid Tumors

Apr 28, 2025, 6:00 AM EDT - 6 months ago

IDEAYA Biosciences to Participate in Upcoming May 2025 Investor Relations Events

Apr 16, 2025, 8:52 AM EDT - 6 months ago

Ideaya Biosciences: These Prices Are Probably Going To Look Cheap Sooner Than Later

Apr 14, 2025, 6:00 AM EDT - 6 months ago

IDEAYA Biosciences Announces Successful FDA Type D Meeting on Phase 3 Registrational Trial Design for Darovasertib as Neoadjuvant Therapy for Primary Uveal Melanoma

Apr 10, 2025, 6:00 AM EDT - 7 months ago

IDEAYA Biosciences Announces Phase 1/2 Expansion for IDE397 and Trodelvy® Combination in MTAP-Deletion Urothelial Cancer

Apr 2, 2025, 11:12 AM EDT - 7 months ago

Why Ideaya Biosciences Is Down Despite Many Positives

Apr 1, 2025, 6:00 AM EDT - 7 months ago

IDEAYA Biosciences Announces Participation in Upcoming April 2025 Investor Relations Events

Mar 31, 2025, 6:00 AM EDT - 7 months ago

IDEAYA Biosciences Receives US FDA Breakthrough Therapy Designation for Darovasertib Monotherapy in Neoadjuvant Uveal Melanoma

Mar 26, 2025, 6:00 AM EDT - 7 months ago

IDEAYA Announces Oral Presentation at the New Drugs on the Horizon Series at AACR 2025 for IDE275 (GSK959), a Phase 1 Werner Helicase Inhibitor

Mar 3, 2025, 6:00 AM EST - 8 months ago

IDEAYA Biosciences Announces Collaboration with ATTMOS to Accelerate AI/ML-Enabled Drug Discovery for Unprecedented First-in-Class Oncology Targets

Feb 13, 2025, 6:05 AM EST - 9 months ago

IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 13, 2025, 6:00 AM EST - 9 months ago

IDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy® and IDE397 in MTAP-Deletion NSCLC

Feb 10, 2025, 4:36 PM EST - 9 months ago

Ideaya Biosciences: Potential Registration-Enabling Darovasertib Study Coming

Feb 10, 2025, 6:00 AM EST - 9 months ago

IDEAYA Biosciences Announces Appointment of Healthcare Investment Banking Veteran Joshua Bleharski as Chief Financial Officer

Jan 27, 2025, 6:00 AM EST - 9 months ago

IDEAYA Biosciences to Participate in Upcoming February 2025 Investor Relations Events

Jan 12, 2025, 12:00 PM EST - 10 months ago

IDEAYA Biosciences Announces Participation at the 43rd Annual J.P. Morgan Healthcare Conference and 2025 Corporate Guidance

Dec 29, 2024, 6:00 AM EST - 10 months ago

IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors

Dec 17, 2024, 6:00 AM EST - 11 months ago

IDEAYA Announces IDMC Recommendation of Move-Forward Dose in Part 2a of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma

Dec 16, 2024, 6:00 AM EST - 11 months ago

IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers

Dec 11, 2024, 6:00 AM EST - 11 months ago

IDEAYA Announces Agenda for Investor R&D Day Webcast on December 16, 2024

Dec 10, 2024, 6:00 AM EST - 11 months ago

IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer

Dec 9, 2024, 6:00 AM EST - 11 months ago

IDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential Best-in-Class MTA-cooperative PRMT5 Inhibitor

Dec 4, 2024, 2:00 PM EST - 11 months ago

Ideaya Biosciences: Long-Tailed Pipeline With Positive Mid-Stage Data And Huge Cash

Dec 2, 2024, 6:00 AM EST - 11 months ago

IDEAYA Biosciences Announces Participation in Upcoming December 2024 Investor Relations Events

Nov 18, 2024, 6:00 AM EST - 1 year ago

IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer

Nov 12, 2024, 6:00 AM EST - 1 year ago

IDEAYA Biosciences Announces Participation in Jefferies London Healthcare Conference and Plans for Investor R&D Day

LiquidThetaLEAPS Oct. 25 at 12:57 PM

0 · Reply

JackDarwin Oct. 25 at 9:15 AM

$IDYA Above the Stomach Candlestick Pattern

0 · Reply

HolEKa1010 Oct. 24 at 3:22 PM

$IDYA okay I see the movement

0 · Reply

LiquidThetaLEAPS Oct. 23 at 10:38 PM

0 · Reply

JarvisFlow Oct. 23 at 3:53 PM

JP Morgan has updated their rating for IDEAYA Biosciences ( $IDYA ) to Overweight with a price target of 79.

0 · Reply

Quantumup Oct. 23 at 11:30 AM

0 · Reply

AVXLIMMINENTZERO Oct. 23 at 7:50 AM

0 · Reply

LiquidThetaLEAPS Oct. 23 at 1:12 AM

0 · Reply

CH_Expat Oct. 22 at 6:56 PM

$IDYA Make of it what you want, but still the one bio I would still open a NEW position with most confidence.

0 · Reply

US_Bull Oct. 22 at 3:55 PM

$IDYA Started a position at 27,5$, 1,300 shares.

0 · Reply

CH_Expat Oct. 21 at 7:51 PM

$IDYA Ah, soft bashing because these scammers want to increase their position.

1 · Reply

JarvisFlow Oct. 21 at 6:02 PM

Goldman Sachs has updated their rating for IDEAYA Biosciences ( $IDYA ) to Neutral with a price target of 30.

0 · Reply

WallStreetBuyDip Oct. 21 at 4:26 PM

$IDYA Massive volume decrease compared to recent days. Price currently at $29.86, with highest at $31.98 and lowest at $14.50. Recent price action shows a significant drop in volume from 1,737,000 to 521,014. Waiting for a lower H% before considering entry.

0 · Reply

JarvisFlow Oct. 21 at 12:08 PM

RBC Capital has adjusted their stance on IDEAYA Biosciences ( $IDYA ), setting the rating to Outperform with a target price of 38 → 41.

0 · Reply

Thestocktraderhubzee Oct. 21 at 10:23 AM

WATCHLIST OCT 21 2025 $LMT Lockheed Martin Says It Has Been Developing Moon Lander Plans That Could Fulfill Nasa's Need For Alternative To SpaceX's Starship $PCRX Pacira Biosciences To Present New Data From Phase 1 Clinical Trial Evaluating PCRX-201, Gene Therapy Candidate For Osteoarthritis Of Knee, At ACR Convergence 2025 Meeting $LPTH LightPath Technologies shares are trading higher after the company announced it received a $4.8 million purchase order for infrared camera systems. $IDYA BTIG Reiterates Buy on IDEAYA Biosciences, Maintains $62 Price Target $WD Walker & Dunlop Secures $40.5M Financing For 137-Unit Affordable Senior Housing Project "The Highlands" In Hyattsville, Maryland

0 · Reply

Quantumup Oct. 21 at 10:16 AM

RBC Capital⬆️the PT on $IDYA to $41 from $38 and reiterated at an Outperform after at ESMO IDYA presented data on eye and visual acuity preservation from daro in the neo-adjuvant setting, building on abstract data in the metastatic setting from Friday. $IMCR $PFE BMY RBC Capital added: Between the two datasets, we see evidence of very impressive anti-tumor efficacy leading to meaningful survival benefits, eye preservation and visual benefits, which we think increase the likelihood that upcoming ph.Ill trials will read out positively. While given the rarity of uveal melanoma, daro may be a somewhat smaller oncology opportunity, we think shares are not reflecting the combination of a ~$1B W.W. net revenue potential for daro and the pipeline assets IDYA has, and we are taking our tgt to $41 on the back of impressive UM data.

0 · Reply

JarvisFlow Oct. 21 at 10:11 AM

BTIG updates rating for IDEAYA Biosciences ( $IDYA ) to Buy, target set at 62.

0 · Reply

BillionerOfKing Oct. 20 at 4:56 PM

$IDYA Current Stock Price: $30.58 Contracts to trade: $30 IDYA Nov 21 2025 Call Entry: $1.50 Exit: $2.72 ROI: 82% Hold ~25 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

notreload_ai Oct. 20 at 12:44 PM

$IDYA shares rise after reporting breakthrough survival data for rare eye cancer treatment combining darovasertib with Pfizer's Xalkori in clinical trial. https://notreload.xyz/ideaya-biosciences-soars-eye-cancer-drug-results/

0 · Reply

OpenOutcrier Oct. 20 at 12:20 PM

$IDYA (+2.5% pre) IDEAYA Biosciences Reports Positive Median Overall Survival Data from Phase 2 Trial of the Darovasertib and Crizotinib Combination in First-line Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress https://ooc.bz/l/81144

0 · Reply

US_Bull Oct. 20 at 10:48 AM

$IDYA This company is a gem just like BPMC it will get swooped up by BP both oncology precision medicine. Chart is also very bullish trying to get in.

1 · Reply

RonIsWrong Oct. 20 at 10:37 AM

$IDYA IDEAYA Biosciences Announces Positive Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma in a Proffered Paper Oral Presentation at ESMO 2025 83% (78/94) of patients demonstrated ocular tumor shrinkage, with 54% (51/94) achieving ≥20% tumor shrinkage 57% (24/42) eye preservation rate in enucleation (EN) recommended patients, which increased to 95% (19/20) in patients achieving ≥20% ocular tumor shrinkage 70% (26/37) of plaque brachytherapy (PB) eligible patients achieved a reduction in predicted radiation dose to the eye from baseline, resulting in 65% (24/37) of patients having lower predicted risk of vision loss 3-years post-PB treatment ~55% (29/53) of EN eligible and ~61% (23/38) of PB eligible patients demonstrated an improvement in baseline visual acuity scores (VAS) during neoadjuvant darovasertib treatment, with a mean gain of 17 and 10 letters, respectively Darovasertib has received U.S. FDA Breakthrough

1 · Reply

Market Cap	2.49B
Revenue (ttm)	7.00M
Net Income (ttm)	-274.48M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-3,921.14%
Debt to Equity Ratio	0.00

Volume	864,100
Avg Vol	1,268,208
Day's Range	N/A - N/A
Shares Out	87.64M
Stochastic %K	59%
Beta	0.14
Analysts	Strong Sell
Price Target	$47.59